Bausch Health's Solta Medical: A Major Milestone in Aesthetic Treatments
In a remarkable achievement that showcases the company's continuous commitment to innovation in medical aesthetics, Solta Medical, a subsidiary of Bausch Health Companies Inc., has announced that it has successfully surpassed the milestone of 10 million aesthetic treatments globally. This remarkable statistic underscores not only the widespread adoption of Solta Medical's cutting-edge aesthetic technologies but also its established leadership in the burgeoning aesthetics market.
Founded over two decades ago, Solta Medical has made significant strides in advancing medical aesthetics through science-driven innovation. The company's portfolio includes popular and effective technologies such as
Thermage®,
Fraxel®,
Clear + Brilliant® Touch, and
VASERlipo®, each designed to meet diverse patient needs while ensuring high safety standards.
Key Technologies and Their Impact
1.
Thermage®: This technology is known for its non-invasive skin tightening capabilities. It employs radiofrequency energy to stimulate collagen production, resulting in firmer, smoother skin. With over
7 million Thermage® tips sold worldwide, this flagship product reflects consumers' trust and satisfaction in its efficacy.
2.
Fraxel®: Renowned for its laser skin resurfacing properties, Fraxel® effectively addresses a range of skin concerns, including wrinkles, age spots, and acne scars. It utilizes non-ablative laser technology, making it a popular choice among patients seeking rejuvenation without significant downtime.
3.
Clear + Brilliant® Touch: This system offers gentle laser treatments targeted at improving skin tone and texture, appealing to those looking for milder interventions that can be integrated into regular skincare routines.
4.
VASERlipo®: This technology stands out in the field of body contouring. It uses ultrasound technology for the targeted and minimally invasive removal of fatty tissues, with a focus on achieving aesthetic goals while minimizing recovery time.
Continued Leadership and Customer Trust
The impressive achievement of reaching 10 million treatments is a testament to Solta Medical’s sustained growth and innovation in the aesthetic industry. With evolving consumer expectations and a growing focus on personalized treatment options, the company remains committed to enhancing its product offerings.
Jiny Kim, Senior Vice President at Solta Medical, highlighted that this milestone indicates not just a number but reflects the enduring trust that both healthcare providers and consumers place in their technologies. He emphasized the company's dedication to clinical differentiation that meets the changing needs of patients.
Thomas J. Appio, CEO of Bausch Health, reiterated the importance of Solta Medical within the overall strategic vision of Bausch Health, aiming to enhance its already established global presence while leveraging its innovative portfolio in the aesthetic market.
Looking Ahead
As Solta Medical builds on this success, it aims to continue pushing the boundaries of innovation in medical aesthetics, developing solutions that enhance patient satisfaction while ensuring safety and efficacy. The company's ongoing commitment to research and development paves the way for exciting advancements in the field, promising a bright future for both Solta Medical and the aesthetics industry as a whole.
For more information about Solta Medical and its innovative product offerings, please visit their official website at
www.solta.com.
While the past two decades have been marked by remarkable achievements and milestones, the journey for Bausch Health and Solta Medical is far from over. As they strive to meet the evolving demands of the aesthetic market, the future looks promising for those seeking safe and effective aesthetic treatments.